samedan logo
 
 
 
spacer
home > ebr > summer 2004 > panacea in the pipeline - promising drug development efforts offer hope to cancer patients
PUBLICATIONS
European Biopharmaceutical Review

Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients

The fight against cancer is one of the most arduously fought battles that the global pharmaceutical industry is engaged in. Cancer therapeutics R&D has evolved over the years in its attempt to find the cure for cancer in its many avatars. We might not know all about cancer and how to conquer it even today, but our knowledge about cancer and the therapeutic interventions is significant, given what it was even as recently as a decade ago. Basic and applied research in oncology has evolved by leaps and bounds, and there are more players with increasingly new approaches and a considerably growing number of pipeline drugs that are trying to tackle some of the biggest killer cancer types. Newer technologies and novel techniques have been deployed by the industry in this pitched battle; emerging and nascent disciplines like biotechnology and nanotechnology hold a lot of promise. This article takes a look at some of these efforts to understand what is in store for millions of hopeful cancer patients across the world.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division

Rajaram Sankaran is an Industry Analyst for Frost and Sullivan's Technical Insights Division, tracking advances in the pharmaceuticals, biotechnology, medical devices and diagnostic imaging industries. He is currently working on a research service entitled 'Nanomedicine - Global Developments and Growth Opportunities'. Previous experience includes assignments for Procter and Gamble, Roche Molecular Diagnostic Systems and two of India's top 10 pharmaceutical companies, Lupin Laboratories and Ranbaxy Laboratories. Rajaram graduated from Nagarjuna University in Physical Sciences and completed postgraduate studies in Management at IIFM, Bhopal.

spacer
Rajaram Sankaran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Language Weaver now available for ServiceNow customers

RWS, the world’s leading provider of technology-enabled language, content management, and intellectual property services, has released a new Language Weaver Connector for ServiceNow
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement